Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements

Core Points - Biomerica, Inc. has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price requirement of $1.00 per share, extending the deadline to May 5, 2025 [1][2] - The company currently meets all other Nasdaq listing requirements, except for the bid price [2] - To regain compliance, Biomerica's stock must close at or above $1.00 for at least ten consecutive business days before the deadline [3] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products for medical conditions [4] - The company primarily targets gastrointestinal and inflammatory diseases, with multiple diagnostic and therapeutic products in development [4] Product Highlight - The inFoods IBS test assesses patients' immunoreactivity to specific foods using a finger-stick blood sample, allowing for targeted dietary recommendations to alleviate IBS symptoms [5] - Clinical studies have shown that patients using the inFoods IBS treatment diet experienced a greater than 30% reduction in abdominal pain compared to those on a placebo diet, indicating clinical significance [5]